BMS-986251

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
BMS-986251
DrugBank Accession Number
DB19007
Background

BMS-986251 is under investigation in clinical trial NCT03329885 (A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 667.61
Monoisotopic: 667.163869516
Chemical Formula
C30H29F8NO5S
Synonyms
  • (1R,3S,4R)-4-((3AR,9BR)-9B-((4-FLUOROPHENYL)SULFONYL)-7-(PERFLUOROPROPAN-2-YL)-2,3,3A,4,5,9B-HEXAHYDRO-1H-BENZO(E)INDOLE-3-CARBONYL)-3-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID
External IDs
  • BMS-986251

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
2WQX2MS3MQ
CAS number
2041841-30-7
InChI Key
JQORWGARJVSRBA-QOTTZFGFSA-N
InChI
InChI=1S/C30H29F8NO5S/c1-16-14-18(26(41)42)2-9-22(16)25(40)39-13-12-27(45(43,44)21-7-5-20(31)6-8-21)23-10-4-19(15-17(23)3-11-24(27)39)28(32,29(33,34)35)30(36,37)38/h4-8,10,15-16,18,22,24H,2-3,9,11-14H2,1H3,(H,41,42)/t16-,18-,22-,24-,27-/m1/s1
IUPAC Name
SMILES
[H][C@@]12CCC3=CC(=CC=C3[C@@]1(CCN2C(=O)[C@@H]1CC[C@H](C[C@@H]1C)C(O)=O)S(=O)(=O)C1=CC=C(F)C=C1)C(F)(C(F)(F)F)C(F)(F)F

References

General References
Not Available
ChemSpider
115009484
BindingDB
50541922
ChEMBL
CHEMBL4634542
PDBe Ligand
R7V

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
1, 2TerminatedTreatmentAnkylosing Spondylitis (AS) / Inflammatory Bowel Diseases (IBD) / Psoriasis / Rheumatoid Arthritis / Steatohepatitis, Nonalcoholic1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at June 28, 2024 17:45 / Updated at June 29, 2024 07:29